Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
Condition: PCNSL Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Methotrexate; Drug: Temozolomide Sponsor: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials